Prima Materia

Prima Materia is the investment vehicle co-founded by Daniel Ek of Spotify, operating from Stockholm with a mandate to deploy concentrated capital into deep tech and AI companies aiming at large-scale disruption of biological and industrial systems. The firm is unusual in European venture for its check-size profile and its explicit willingness to take very large positions in a small number of companies.

The healthcare thesis covers digital health and AI/ML in healthcare, with a strong bias toward companies whose ambition extends to reshaping how biology and clinical care are practiced rather than incremental workflow improvement. That framing is consistent with the firm’s broader posture: long horizons, high conviction, and tolerance for scientific and technical risk that most growth-stage investors will not absorb. Specific portfolio companies are not enumerated in the source material, so founders should request direct references in diligence and ask explicitly about prior healthcare-specific commitments.

Prima Materia invests at Series A and Series B, with checks of twenty-five million dollars and above. That positions the firm as a lead or co-lead in larger growth-stage rounds for companies that are genuinely capital-intensive, rather than as a generalist Series A investor. The geographic focus is global with European concentration, and the firm has been comfortable backing companies across multiple geographies when the underlying ambition matches its thesis. For founders, that means Prima Materia is most relevant when the next round is large by European standards and the thesis requires patient, concentrated capital rather than syndicated incremental funding.

The team is composed of partners and operators with founder and large-scale technology operating backgrounds. Specific partner names beyond Daniel Ek are not provided in the source material, and founders should clarify partner ownership of healthcare investments and the practical decision-making process directly.

The right founders for Prima Materia are growth-stage technically ambitious teams in health AI or applied biology where capital intensity is genuine and the company’s ambition is on the scale the firm is built for. The wrong founders are small-check or efficiency-led teams, where the fund’s size and posture do not match the actual financing need. Founders should arrive with a credible long-horizon technical roadmap, capital plan that reflects real scientific or engineering complexity, and clear-eyed thinking about how concentrated ownership by an ambitious investor changes board dynamics and exit optionality. Prima Materia rewards specificity about ambition and is unlikely to be the right partner for companies that are quietly trying to be smaller than they say.